Login to Your Account

Ablynx, PTC In $100M-Plus Deals

Seattle Genetics, Genentech Sign $860M Deal For Cancer Antibody

By Jennifer Boggs

Tuesday, January 9, 2007
Topping the spate of high-dollar collaborations announced Monday, Seattle Genetics Inc. signed Genentech Inc. to a potential $860M partnership to develop SGN-40, a monoclonal antibody in early clinical testing in hematologic cancers. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription